Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF and Norfloxacin for SBP Secondary Prophylaxis
NCT03702426Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of sargramostim in spontaneous bacterial peritonitis (SBP), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Spontaneous Bacterial Peritonitis on secondary prophylaxis at 6 months. Started Jul 2018; status: completed.
02
Drugs
sargramostim
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT03702426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702426.